PSA Testing and Prostate Cancer Mortality: Evidence Review
This paper examines the controversial question of whether prostate-specific antigen (PSA) testing reduces prostate cancer mortality rates, using an evidence-based nursing practice framework. It identifies PSA screening as a contentious clinical issue, reviews competing research findings, and critically evaluates the evidence. While some studies suggest modest mortality benefits, the weight of evidence indicates that mass PSA testing does not significantly reduce prostate cancer deaths and is associated with overdiagnosis, overtreatment, and psychological harm. The paper concludes by recommending personalized PSA testing — incorporating individual risk factors such as age, family history, race, and genetic variants — as the most suitable evidence-based alternative to population-wide screening campaigns.
- Introduction: Overview of PSA testing controversy and paper scope
- Controversial Issue and Background: Prostate cancer statistics and PSA screening debate
- Literature Review: Key studies on PSA testing and mortality outcomes
- Analysis of Research Evidence: Weighing contradictory PSA mortality evidence
- Most Suitable Alternative to PSA Testing: Personalized PSA testing as evidence-based intervention
- Conclusion: PSA testing verdict and recommended alternative
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Clearly frames a genuine clinical controversy and maintains that framing consistently throughout each section, helping readers understand why the issue matters.
- Presents both sides of the PSA debate before weighing the evidence, demonstrating intellectual fairness while ultimately building a well-supported conclusion.
- Moves purposefully from problem identification to literature review to analysis to a concrete alternative intervention, giving the paper a practical, applied orientation.
Key academic technique demonstrated
The paper demonstrates systematic evidence synthesis within an evidence-based practice (EBP) framework. Rather than simply listing sources, the author evaluates competing studies for methodological strength, flags unverifiable methodology in pro-PSA research, and uses that critique to justify its conclusion. This mirrors the appraisal step used in clinical EBP protocols.
Structure breakdown
The paper follows a four-part EBP structure: (1) identification of the controversial problem, (2) search and presentation of relevant literature, (3) critical evaluation of that evidence, and (4) recommendation of the most suitable intervention. Each section maps directly to one EBP step, making the organizational logic explicit and easy to follow. The conclusion concisely restates the central finding and ties it back to the opening problem statement.
Introduction
Prostate cancer screening is considered one of the crucial steps toward addressing prostate cancer among various patient populations. Healthcare providers regard screening as essential to improving patient health and well-being. In light of its significance to health promotion, several screening tools have been developed and are used in clinical settings, including the digital rectal exam (DRE) and prostate-specific antigen (PSA) testing. PSA testing has received considerable attention in recent years, particularly in relation to its impact on mortality rates.
PSA testing and screening for prostate cancer remain controversial in the modern healthcare setting, given the variance in evidence regarding its effect on mortality rates. This paper examines whether PSA testing reduces mortality rates based on research evidence and evidence-based practice. The analysis is organized around four major steps in evidence-based nursing practice: identification of the controversial problem, search for relevant research studies, evaluation of research evidence, and identification of the most suitable intervention.
Controversial Issue and Background
The controversial issue examined in this paper is PSA testing and its relationship to prostate cancer mortality rates in today's clinical setting. According to Vis (2002), PSA-based testing or screening for prostate cancer is one of the major controversial issues in the modern healthcare sector. PSA testing was established following the increased availability of valid screening tests and the likelihood of success of curative treatment alternatives for prostate cancer. Healthcare providers and authorities in the United States have continued to advocate for PSA testing on the basis of these factors.
Prostate cancer is one of the most common and frequent causes of cancer-related death among men aged 65 years or older. It is reported that prostate cancer is the third leading cause of cancer-related death among American men, following lung cancer and colorectal cancer. Lung cancer accounts for 44.7% of cancer-related deaths, colorectal cancer accounts for 21.2%, and prostate cancer accounts for 20% (Cancer Statistics Center, 2017). The lifetime risk for American men to develop prostate cancer is 16%, whereas the risk of dying from the condition is only 2.9% (American Cancer Society, 2017). Although prostate cancer is a major health problem, most men diagnosed with the condition do not die from it.
Mortality rates associated with prostate cancer have nonetheless received significant attention in the health sector in recent years. Healthcare authorities and professionals consider prostate cancer screening a crucial element in lessening incidence rates, prevalence rates, and mortality rates. Consequently, various tools have been developed to assist in screening, including PSA testing. While PSA testing is regarded as an important tool for prostate cancer screening, it remains controversial — particularly in relation to its impact on mortality rates — and is the central subject of this paper.
References
American Cancer Society, Inc. (2017). Key statistics for prostate cancer. Retrieved October 31, 2017, from https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html
Begley, S. (2017, September 5). Do prostate cancer screenings significantly reduce deaths? Scientific American. Retrieved October 31, 2017, from https://www.scientificamerican.com/article/do-prostate-cancer-screenings-significantly-reduce-deaths/
Cancer Statistics Center. (2017). 2017 Estimates. Retrieved November 3, 2017, from https://cancerstatisticscenter.cancer.org/#!/
Carter, H. B., et al. (2011). Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. The Journal of the American Medical Association, 277(18), 1456–1460.
Gulati, R., Gore, J. L., & Etzioni, R. (2013, February 5). Comparative effectiveness of alternative PSA-based prostate cancer screening strategies. Annals of Internal Medicine, 158(3), 145–153.
Helfand, B. T., et al. (2013, May). Personalized PSA testing using genetic variants may reduce unnecessary prostate biopsies. Journal of Urology, 189(5), 1697–1701.
Howrey, B. T., et al. (2013, January). The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States. The Journal of Gerontology, Series A: Biological Sciences and Medical Sciences, 68(1), 56–61.
Mitka, M. (2012, January 6). Study: Mass PSA screening does not reduce risk of dying from prostate cancer. Retrieved October 31, 2017, from
Mulhem, E., Fulbright, N., & Duncan, N. (2015, October 15). Prostate cancer screening. American Family Physician, 92(8), 683–688. Retrieved from http://www.aafp.org/afp/2015/1015/p683.html
Nelson, R. (2014, August 6). PSA screening does reduce deaths, but is not recommended. Retrieved October 31, 2017, from https://www.medscape.com/viewarticle/829507
Slatkoff, S., et al. (2011, June). PSA testing: When it's useful, when it's not. The Journal of Family Practice, 60(6), 357–360. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3183963/
Vis, A. N. (2002, March 5). Does PSA screening reduce prostate cancer mortality? Canadian Medical Association Journal, 166(5), 600–601. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC99402/
Wilt, T. J., et al. (2014, March 1). Prostate-specific antigen screening in prostate cancer: Perspectives on the evidence. Journal of the National Cancer Institute, 106(3). Retrieved from
Create your account
Always verify citation format against your institution’s current style guide requirements.